AlloVir Inc
ALVR
Market Cap$49.48M
Close$
$1.02
89.6% downside
Current Fair Value
89.6% downsideOvervalued by 89.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $49.48 Million |
|---|---|
| Enterprise Value | $-38,950,638.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-11.73 |
| Beta | 0.62 |
| Outstanding Shares | 18,701,286 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.17 |
|---|---|
| PEG | -1.35 |
| Price to Sales | - |
| Price to Book Ratio | 4.91 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.81 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Kalaris Therapeutics Inc
14 employees
CEO: Mr. Andrew Oxtoby Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.